Comparing the PCV7
and PCV13 time periods, the mean number of OM visits per 100 children declined from 84 to 64 per 100 children younger than 2 years, 41 to 34 per 100 children between ages 2 and 5 years, and from 59 to 46 per 100 children younger than 5 years.
The NP carriage rate of children vaccinated with PCV7
(3+1) was 21.4% (3/14), whereas it was 11.7% (6/51) in children vaccinated with PCV13 (3 doses) and 14.4% (12/83 children) in those with PCV13 (3+1).
(vi) the negative driver of the PCV7-types IPD rate in adults is the childhood PCV program computed as a function of the time elapsed since the introduction of PCV7
in December 2004, representing the indirect (herd) protection ;
A 5.4% reduction in antibiotic prescriptions was recorded after the introduction of PCV7
at the Kaiser Permanente clinics in Northern California, as well as a 12.6% decrease in second-line antibiotic prescriptions. Overall, PCV7
prevented 35 antibiotic prescriptions per 100 vaccinated children.
Furthermore, among antimicrobial non-susceptible isolates including [beta]-lactamase, macrolides and sulfonamides, the coverage rates of PCV7
types were significantly higher than non-PCV7 types (p < 0.05).
Pneumonia hospitalization rates were fairly stable in the pre-PCV period, declined substantially after PCV7
introduction, and were lower yet after PCV13 introduction.
The rates of local reactions, systemic events, and AEs observed were similar to those reported in previous trials comparing PCV13 with PCV7
given as a 3 + 1 series with routine pediatric vaccines (10, 14, 16).
The capsule is one target of a vaccine called PCV7
, first introduced in 2000.
The number of children admitted to English hospitals with bacterial pneumonia decreased by one-fifth in the two years following introduction of the seven-valent pneumococcal conjugate vaccination (PCV7
), a study has found.
In September 2006, a vaccine known as PCV7
was introduced into the childhood primary immunisation programme across the UK, to protect against seven different strains of Streptococcus pneumoniae bacteria.
(1) PCV13 is meant to replace the 7-valent PCV7
(Prevnar), and will offer protection against a wider array of pneumococcal serotypes.
An efficacy of >80% for a 7-valent vaccine (PCV7
, Pfizer (previously Wyeth Pharmaceuticals), containing serotypes 4, 6B, 9V, 14, 18C, 19F and 23F PCV) against IPD has been documented in two large vaccine trials in the USA using a dosing schedule of 2, 4 and 6 months with a booster dose at 12 - 15 months.
In Israel, the 7-valent PCV (PCV7
) was introduced to the national immunization plan (NIP) in July 2009, with a catch-up plan for children <2 years of age, and was gradually replaced with the 13-valent PCV (PCV13) in November 2010, without further catch-up.